Welcome to our dedicated page for Verve Therapeutics SEC filings (Ticker: VERV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Verve Therapeutics filings document the formal wind-down of its public-company registration following the completed acquisition by Eli Lilly and Company. The record includes acquisition-related Form 8-K material-event reports, common-stock listing information for the Nasdaq Global Select Market, a Form 25 notification removing the common stock from exchange listing and Section 12(b) registration, and a Form 15 terminating or suspending Exchange Act reporting duties for the common stock.
Earlier disclosure categories included material agreements, shareholder voting matters, governance matters, capital-structure disclosure, operating and financial results, risk factors, and clinical or regulatory information related to Verve's genetic-medicine programs for cardiovascular disease.